Backed by the Japanese Zeria Group, fast growing gastrointestinal (GI) specialist Tillotts Pharma is looking to acquire further GI assets after its recent USD 200m M&A deal. The company is looking for assets which generate a turnover of EUR 50 - 150 million in Europe and/or Japan, and also to enter into a strategic partnership with a GI focused US based company. CEO Thomas A. Tóth von Kiskér discusses some of the barriers to growth that SMEs face today in an increasingly consolidated industry.
From a product development perspective, as regulatory hurdles are constantly increasing, so is the price of the development: the average cost of developing a drug with a new chemical entity has surpassed USD 1.5 billion
